Equities

Aarti Pharmalabs Ltd

AARTIPHARM:NSI

Aarti Pharmalabs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)607.05
  • Today's Change-1.70 / -0.28%
  • Shares traded385.55k
  • 1 Year change+71.58%
  • Beta--
Data delayed at least 15 minutes, as of May 23 2024 11:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), xanthine derivatives, and allied products, situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, and others. Its Caffeine products include caffeine anhydrous, and caffeine anhydrous (granules).

  • Revenue in INR (TTM)18.53bn
  • Net income in INR2.17bn
  • Incorporated2019
  • Employees1.40k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn29.77bn1.23k--94.14----------12.72------------------------0.8228--0.2681--43.84--77.37------
Supriya Lifescience Ltd5.54bn1.20bn29.94bn392.0024.85--22.135.4014.9714.9768.93--------14,144,410.00--20.77--29.0661.9455.8321.7224.33--63.63--2.02-13.0416.70-40.8159.4185.55--
Dishman Carbogen Amcis Ltd25.80bn-1.54bn30.13bn1.30k----20.451.17-9.84-9.84164.35--------19,919,850.00--0.4699--0.566576.9374.36-5.981.82---0.1245--202.7612.727.32-265.46--21.54--
Gufic BioSciences Ltd7.85bn841.95m34.62bn1.63k40.04--32.824.418.628.6280.38--------4,820,074.00--12.30--23.0851.0844.9110.739.84--8.22--1.39-11.3617.47-16.8437.0686.8214.87
Hikal Ltd17.85bn696.00m37.20bn2.14k53.403.1319.872.085.655.65144.7796.320.73252.663.60--2.865.074.037.5153.7947.223.905.860.87612.650.407716.88-11.792.34-11.20-7.559.720.00
Unichem Laboratories Ltd17.05bn-704.74m39.98bn3.12k--1.6993.482.34-10.02-10.02238.88335.540.53590.99952.84---2.22-1.67-2.81-2.0361.0257.79-4.13-3.991.40-0.57330.0948--26.947.6465.15---35.00--
Advanced Enzyme Technologies Ltd6.24bn1.33bn41.79bn338.0031.323.1624.276.7011.9311.9355.83118.410.42191.066.27--9.2610.8210.2311.9376.8372.8121.9524.596.2257.810.033415.1715.398.2626.193.7227.8553.42
Aarti Drugs Ltd25.29bn1.71bn45.55bn1.50k26.623.5520.421.8018.6118.61274.44139.401.043.353.22--7.079.7310.9815.7433.6524.966.798.251.057.910.3056---6.9010.133.0713.8224.96--
Shilpa Medicare Ltd11.23bn-6.71m48.19bn1.03k----45.324.29-0.0714-0.0714131.44--------10,873,050.00--3.89--4.9264.4260.22-0.05389.29--1.16--10.65-8.335.82-153.54--14.58--
Orchid Pharma Ltd8.12bn1.25bn54.67bn838.0037.82--34.396.7328.5026.84175.33--------9,691,729.00---1.07---1.9641.4945.8715.63-3.52--4.34----19.00-0.6456187.87--68.72--
Aarti Pharmalabs Ltd18.53bn2.17bn55.17bn1.40k25.433.1419.022.9823.9423.94204.45193.890.76981.643.86--9.01--12.30--44.90--11.71--1.0118.170.1397---4.76--12.10------
Blue Jet Healthcare Ltd-100.00bn-100.00bn65.78bn--------------------------------------------------5.49---11.88------
Sun Pharma Advanced Research Co Ltd1.07bn-3.63bn68.62bn407.00------64.32-11.22-11.223.29--------2,621,133.00---59.13---119.2975.2179.70-340.66-116.46---400.34----73.9825.00-9.43---13.96--
Marksans Pharma Ltd21.03bn3.17bn75.57bn1.40k23.66--19.523.597.057.0546.71--------15,024,090.00--14.78--19.5851.8850.1615.2113.01--44.45--5.4924.2315.2044.2951.896.6158.49
F D C Ltd19.16bn2.90bn78.37bn6.37k27.31--23.844.0917.6317.63116.59--------3,006,457.00--11.68--13.2965.7262.0315.1115.85--70.61--1.2216.7410.49-10.342.2625.03--
Procter & Gamble Health Ltd11.69bn2.14bn79.39bn1.41k37.12--32.976.79128.85128.85703.49--------8,305,331.00--------70.45--18.31----400.33----10.34--19.19------
Data as of May 23 2024. Currency figures normalised to Aarti Pharmalabs Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

6.75%Per cent of shares held by top holders
HolderShares% Held
Morgan Stanley Investment Management Co.as of 31 Mar 2024974.85k1.08%
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Apr 2024954.62k1.05%
BAMCO, Inc.as of 29 Feb 2024940.27k1.04%
BlackRock Fund Advisorsas of 09 May 2024733.15k0.81%
ICICI Prudential Asset Management Co. Ltd.as of 30 Apr 2024599.33k0.66%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Apr 2024496.33k0.55%
quant Money Managers Ltd.as of 30 Apr 2024495.85k0.55%
Dimensional Fund Advisors LPas of 09 May 2024443.79k0.49%
Norges Bank Investment Managementas of 31 Dec 2023341.42k0.38%
BlackRock Advisors (UK) Ltd.as of 09 May 2024133.58k0.15%
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.